Generex Biotechnology Corporation is engaged primarily in the research and development of drug delivery technologies. The Company's primary focus is the development of its technology for the administration of formulations of large molecule drugs to the oral (buccal) cavity using a hand-held aerosol applicator. The Company's buccal delivery technology involves the preparation of a formulation in which an active pharmaceutical agent is placed in a solution with a combination of absorption enhancers and other excipients classified generally recognized as safe (GRAS) by the United States Food and Drug Administration (FDA) when used in accordance with specified quantity and other limitations. The resulting formulation is aerosolized with a pharmaceutical grade chemical propellant and is administered to the patient using the Company's RapidMist device.